Clearmind Medicine Secures Six Hong Kong Patents for PEA-Psychedelic Combination Therapies
Clearmind Medicine's six patents published by Hong Kong IP Department cover PEA combinations with MDMA, LSD, ketamine, ibogaine, psilocybin and DMT, expanding its neuroplastogen-based therapy portfolio. These patents reinforce worldwide intellectual property protection as the company advances novel psychedelic-derived treatments for mental health and neurological disorders.
1. Patent Publication Details
Clearmind Medicine announced that the Intellectual Property Department in Hong Kong has published six new patents covering proprietary combination formulations of palmitoylethanolamide paired individually with MDMA, LSD, ketamine, ibogaine, psilocybin and DMT.
2. Therapeutic Potential
These patent-protected formulations aim to enhance safety, tolerability and neuroplasticity in treatments for mental health and neurological disorders, positioning Clearmind’s novel psychedelic-derived candidates as differentiated therapeutic options.
3. IP Portfolio Expansion
These additions augment Clearmind’s nineteen patent families and 31 granted patents, underscoring a proactive strategy to secure global intellectual property as it advances its clinical-stage neuroplastogen pipeline.